Table 2.
Summary of literature of the CSF determination of PGRN levels in CNS diseases
| conditions | case number | PGRN concentration (ng/ml) | statistics | method | Ref | ||
|---|---|---|---|---|---|---|---|
| 1 | Control | 40 | Median (range) 4.3 (2.3–7.0) | ELISA (adipogene) | (Steinacker et al., 2011) | ||
| ALS | 68 | 3.9 (2.2–8.2) | ns | ||||
| PD | 20 | 4.1(2.6–4.5) | ns | ||||
| 2 | MS | total | 40 | Mean ±SD 21.32±4.2 | ELISA (adipogene) | (Vercellino et al., 2011) | |
| * RRMS during remission | 20 | 14.56±4.16 | |||||
| RRMS during relapse | 10 | 31.26±5.62 | ** | ||||
| * SPMS | 10 | 24.92±3.03 | ** | ||||
| Non-inflammatory control, with neurological diseases | 15 | 17.15±4.92 | ns | ||||
| Viral encephalitis; Inflammatory control | 5 | 76.38±85.08 | ** | ||||
| 3 | MS | 55 | Mean ±SEM 5.99±0.25 | ELISA (adipogene) | (De et al., 2010) | ||
| Non-inflammatory Neurologic diseases | 35 | 5.95±0.35 | ns | ||||
| Viral meningitis, optic neuritis, SLE (Other inflammatory neurologic diseases) | 7 | 8.20±1.69 | ns | ||||
| Control | 8 | 6.48±0.65 | ns | ||||
| 4 | control | 31 | Mean ±SEM 6.4±0.6 | ELISA (R&D ) | (Philips et al., 2010) | ||
| ALS | 29 | 7.0±0.5 | ns | ||||
| FTLD no PGRN mutation | 24 | 6.9±0.6 | ns | ||||
| FTLD, PGRN mutation | 3 | 2.2±1.0 | * | ||||
| FTLD+ALS | 4 | 5.5±0.7 | ns | ||||
| AD | 34 | 6.0±0.5 | ns | ||||
| 5 | Healthy control | 5 | Mean ±SD 8.2±2.7 | ELISA (adipogene) | (Ghidoni et al., 2008) | ||
| FTLD, no PGRN mutation | 17 | 8.7±2.1 | ns | ||||
| FTLD, PGRN mutation | 5 | 3.7±0.6 | * | ||||
*
RRMS = relapsing remitting MS, SPMS = secondary progressive MS (* p <0.05, ** p <0.01, ns = not significant)